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Multiplex ligation-dependent probe amplification
enhances molecular diagnosis of Diamond-
Blackfan anemia due to RPS19 deficiency
Diamond-Blackfan anemia (DBA,#MIM105650) is a
rare congenital pure red cell aplasia characterized by nor-
mochromic macrocytic anemia, reticulocytopenia, and
normocellular bone marrow with a selective deficiency of
erythroid precursors. Defects in the RPS19 gene on chro-
mosome 19q13.2 are the main known cause of DBA and
account for 20-25% of DBA patients.1-3 This gene com-
prises six exons that span ~11 kb of genomic DNA, and
encodes the ribosomal protein S19. Mutations in the
RPS24 and RPS17 genes have been reported, though they
are only mutated in a minority of patients.4,5 The 8p23.3-
8p22 region has also been implicated in DBA, but the
gene has not yet been identified.6 Eighty-three unique
RPS19 mutations scattered throughout the entire gene
and all found in heterozygosity with the wild type
sequence have so far been reported in 127 families.7 Since
only 8 patients have been found to carry a complete or
partial RPS19 deletion, it may be supposed this category
of mutations is present in around 6% of RPS19-mutated
patients.7 Standard PCR-based methods used for conven-
tional mutation detection fail to identify heterozygous
deletions because the normal allele masks the deleted
segment. In sequence analysis, apparent loss of heterozy-
gosity of one or more intragenic single nucleotide poly-
morphisms (SNPs) may be the only sign of a deletion in
family studies. Strategies that detect copy number varia-
tions, such as Southern blotting, real-time PCR, and fiber
FISH, are thus necessary to integrate sequencing.
Development of the MLPA (Multiplex Ligation-depend-
ent Probe Amplification) technique to detect complete or
partial gene deletions or duplications has greatly
improved mutation screening.8 This technique is an easy
and sensitive method based on the simultaneous
hybridization and ligation of several probes that matched
to single exons in a single reaction tube, followed by PCR
and analysis by capillary electrophoresis. If a deletion is
present, even on only one exon of a single allele, the cor-
responding peak is reduced (Figure 1); enhanced peaks
suggest duplication.
Here we describe MLPA first application to the RPS19
gene in the molecular diagnosis of DBA.
Routine sequence analysis of the RPS19 gene in 123
DBA patients identified 31 mutated subjects, whereas 92
seemed normal.9 Informed consent was obtained from all
patients included in the study. Our PCR primers also
allow interrogation of six SNPs distributed along the gene
Figure 1. MLPA technique. (A) Denatured genomic DNA is hybridized with a mixture of 23 probes. Each MLPA probe consists of two
oligonucleotides. The two parts of each probe hybridize to adjacent target sequences and are ligated by a thermostable ligase. A uni-
versal primer pair is used to amplify all ligated probes. The amplification product of each probe has a unique length ranging from 130bp
to 400bp. Fragments are separated on an ABI Prism 3100-Avant automatic sequencer by using POP4 polymer and GS-ROX-500 molec-
ular marker (Applera, Foster City, CA, USA), and analyzed with the Genescan software ver.3.1. Relative amounts of probe amplification
products, as compared to control DNA sample, reflect the relative copy number of target sequences. (B) MLPA chromatogram of patient
2 carrying a whole gene deletion and a control subject (n-ctr). RPS19 peaks are labeled with their exon numbers. Unlabeled peaks rep-
resent genes in the 8p23 region and control genes (only the control probe 3544-L2910 is indicated). The values of peak sizes and area
from patients and controls were used and normalized as follows: 1) the area of each peak (As) was divided by the sum of all 23 peak
areas (∑As) of that sample; 2) for each peak this ratio (nAs=As/∑As) was divided by the relative peak area of the corresponding probe
calculated as the average from (two or three) control DNA samples (nAc=Ac/∑Ac). A ratio (nAs/nAc) ranging from 0.8 to 1.2 was con-
sidered as a normal exon dosage; a deletion was suspected for ratio <0.7; a duplication was suspected for ratio >1.3.
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in not coding regions and usually transmitted en bloc.2,10
These SNPs were used to divide the 92 non-mutated
patients into two groups according to their haplotypes.
Heterozygotes were 38/92 (41%). None displayed a loss
of heterozygosity for one or more SNPs, suggesting the
absence of intragenic deletions. Homozygotes were
54/92 (59%). It was assumed that some of them could
carry a complete or partial deletion. MLPA was also used
to look for duplication in both groups. 
MLPA was performed on genomic DNA with the
MLPA DBA test kit (MLPA KIT P212 DBA, MRC-
Holland, Amsterdam, The Netherlands) according to the
manufacturer’s instructions (http://www.mrc-holland.com).
The probemix was composed of 23 probes: six probes
mapped the RPS19 gene (one for each exon), one probe a
region close to RPS19 (8.8 Kb upstream from the exon 1
probe), and ten the 8p23 region formerly suggested as a
candidate for an unknown DBA gene. Six were control
fragments. In each experiment, MLPA efficiency was test-
ed by using a patient carrier of a known complete gene
deletion of the RPS19 gene due to an unbalanced translo-
cation (1;19) (p32; q13).1
MLPA revealed a significant reduction of the peak
heights of all RPS19 exons in 3/54 homozygotes, suggest-
ing the presence of heterozygous deletions of the entire
RPS19 gene.  A probe located 8.8 Kb centromeric to the
RPS19 gene (DMRTC2) was also deleted in these 3
patients. All DNA samples showing evidence of a dele-
tion were confirmed in a second MLPA experiment.
Normal results in the other 89 patients showed the
absence of intragenic deletions and duplications. No
genomic rearrangement was discovered in the 8p23.3-
8p22 region.
MLPA was also performed on the parents of each delet-
ed patient; the absence of abnormalities in both parents
proved that the three deletions were de novo. 
To confirm these deletions, better define their exten-
sion and substantiate parental origin, we analyzed seven-
teen microsatellites spanning the 19q13 region from
D19S47 to D19S178 (~2Mb centromeric and ~2Mb
telomeric to the RPS19 gene).11,12 We also analyzed a
microsatellite internal to ARHGEF1 gene using a forward
fluorescently-labeled primer 5’-TAGTTGTGGGGT-
CAGGATGG-3’ and a reverse primer 5’-GAAGTTCCTC-
CCCGACTTCT-3’.
We found that the extension of the deletions varied
from ~0.06 to ~3Mb; the deletion was of maternal origin
in patients 1 and 2, and paternal origin in patient 3 (Figure
2). These patients (2 males, 1 female) displayed early-
onset anemia (age at diagnosis 0-4 months) and malfor-
mations: cranio-facial dysmorphisms, strabismus and uro-
genital malformations (patient 1), growth retardation
(patient 2), and cardiac malformations (patient 3).  Patient
1 was also mentally retarded. Initial steroid response was
reported in patients 1 and 3; patient 3 died of sepsis dur-
ing the first steroid course. Patient 2 was steroid unre-
sponsive and therefore transfusion dependent. 
Like other authors, we found MLPA efficient and rapid
for analysis of gene dosage alterations.8 In this study, it
identified three unsuspected heterozygous RPS19 gene
deletions missed by standard mutation screening PCR-
based methods. Mutation screening of the RPS19 gene
with a combination of sequencing and MLPA reached an
overall rate of 28% (34/123). This was equivalent to a 3%
increase in the detection rate compared to sequencing
alone. Furthermore, whereas the frequency of genomic
deletions in DBA patients was previously at 6% of RPS19
alterations,7 this rises to 8.5% on the strength of our
results.  In our cohort, genomic deletions represent up to
12% of all mutations detected.
In conclusion, we stress that a gene-dosage technique,
such as MLPA or FISH, should complement sequencing in
a clinical environment since only a combined approach of
this kind permits comprehensive detection of all muta-
tions within the RPS19 gene. We strongly suggest that it
should be applied as a complement to RPS19 sequencing
to all subjects with a DBA phenotype.
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Immune-mediated pure red cell aplasia in renal
transplant recipients
Pure red cell aplasia (PRCA) is defined by an isolated
severe anemia, contrasting with a normal white blood cell
and platelet counts, severe reticulocytopenia  and a selec-
tive absence of erythroid progenitors in the bone marrow
smears.1 Although an immune origin is involved in the
majority of cases,1 the diagnosis of immune-mediated
cytopenia is rarely considered in organ transplant recipi-
ents, given the immunocompromised status. Etiologies of
post-transplant PRCA are rather dominated by chronic
parvovirus B19 infections2 and drug-induced bone mar-
row toxicity.3 However, in most cases reported in the lit-
erature with drug-induced PRCA, cyclosporine A (CyA)
was introduced to replace the incriminated drug. We,
therefore, hypothesized that some post-transplant PRCA
may be immune-mediated, especially in renal transplant
recipients treated with a calcineurin inhibitor (CNI)-free
regimen. This hypothesis is supported by an unexpected-
ly high frequency of LGL-like clonal disorders in organ
transplant recipients,4 and by a recent report of autoim-
mune cytopenia occurring in up to 5.6% of pancreas
transplant recipients receiving a calcineurin inhibitor-free
regimen.5 We report here 3 renal transplant recipients
admitted for PRCA, in whom thorough investigations
provided compelling evidence of immune mechanisms.
End stage renal failure was related to chronic primary
glomerulonephritis in all of them, and they all received a
first renal transplant in the early ‘80s. Between 1980 and
1990, 489 out of the 611 patients receiving a renal trans-
plant in our center were given a calcineurin inhibitor
(CNI)-free immunosuppressive regimen, including the 3
cases who later experienced immune-mediated PRCA. 
The 3 patients were admitted for severe aregenerative
anemia, while treated with prednisone and azathioprine
for several years. Bone marrow smears confirmed the
diagnosis of PRCA. None of them was given recombinant
erythropoietin and the high erythropoietin levels found in
our patients excluded the hypothesis of anti-erythropoi-
etin antibodies (Table 1).  Parvovirus B19 infection is a
well-identified cause of PRCA in immunocompromized
patients.2 However, both serology and specific PCR ruled
out this hypothesis in our 3 cases. A specific azathioprine-
Table 1. Laboratory examination of 3 patients with immune-medi-
ated PRCA. Erythroid progenitors cultures were performed with
5×105 cells/mL. Values are means of duplicate culture of day 7
CFU-E-derived colonies per 5×105 plated cells.
Normal Case 1 Case 2 Case 3
Values
1st flare / 2nd flare
Mean corpuscular 
volume (fL) 80-100 105 105 100
Erythropoietin 4-14 1666 / 1920 ND 1220  
(mU/mL)
Parvovirus B19   IgM − / ND − −
IgG + / ND + +
PCR − / − − −
T-cell clone + / + + +
LGL population ND + ND ND
Coomb’s reaction − / − − −
ANA − − −
CFU-E-derived colonies 100-1,000
patient’s serum 155 / ND 135 ND
control’s serum 105 / ND 65 ND
ANA: anti-nuclear antibody; LGL: large granular lymphocyte; ND: not done;
PCR: polychain reaction; (+), positive; (-), negative.
